372 related articles for article (PubMed ID: 30043261)
21. Protein misfolding in neurodegenerative diseases.
Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
[TBL] [Abstract][Full Text] [Related]
22. Contribution of glutamatergic signaling to nitrosative stress-induced protein misfolding in normal brain aging and neurodegenerative diseases.
Nakamura T; Gu Z; Lipton SA
Aging Cell; 2007 Jun; 6(3):351-9. PubMed ID: 17388798
[TBL] [Abstract][Full Text] [Related]
23. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
[TBL] [Abstract][Full Text] [Related]
24. Cell death: protein misfolding and neurodegenerative diseases.
Nakamura T; Lipton SA
Apoptosis; 2009 Apr; 14(4):455-68. PubMed ID: 19130231
[TBL] [Abstract][Full Text] [Related]
25. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.
Noble W; Garwood CJ; Hanger DP
Prion; 2009; 3(2):78-83. PubMed ID: 19458490
[TBL] [Abstract][Full Text] [Related]
26. Engineering enhanced protein disaggregases for neurodegenerative disease.
Jackrel ME; Shorter J
Prion; 2015; 9(2):90-109. PubMed ID: 25738979
[TBL] [Abstract][Full Text] [Related]
27. Monitoring autophagy in the treatment of protein aggregate diseases: steps toward identifying autophagic biomarkers.
Weihl CC
Neurotherapeutics; 2013 Jul; 10(3):383-90. PubMed ID: 23408309
[TBL] [Abstract][Full Text] [Related]
28. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.
Guest WC; Silverman JM; Pokrishevsky E; O'Neill MA; Grad LI; Cashman NR
J Toxicol Environ Health A; 2011; 74(22-24):1433-59. PubMed ID: 22043906
[TBL] [Abstract][Full Text] [Related]
29. Protein homeostasis in neurons and its pathological alterations.
Malgaroli A; Vallar L; Zimarino V
Curr Opin Neurobiol; 2006 Jun; 16(3):270-4. PubMed ID: 16713705
[TBL] [Abstract][Full Text] [Related]
30. Theoretical and computational advances in protein misfolding.
Biswas P
Adv Protein Chem Struct Biol; 2019; 118():1-31. PubMed ID: 31928722
[TBL] [Abstract][Full Text] [Related]
31. Potential Influence of Cyclo(His-Pro) on Proteostasis: Impact on Neurodegenerative Diseases.
Grottelli S; Costanzi E; Peirce MJ; Minelli A; Cellini B; Bellezza I
Curr Protein Pept Sci; 2018; 19(8):805-812. PubMed ID: 29708066
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease.
Skibinski G; Finkbeiner S
FEBS Lett; 2013 Apr; 587(8):1139-46. PubMed ID: 23458259
[TBL] [Abstract][Full Text] [Related]
33. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
Ciechanover A; Kwon YT
Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
[TBL] [Abstract][Full Text] [Related]
34. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.
Victoria GS; Zurzolo C
J Cell Biol; 2017 Sep; 216(9):2633-2644. PubMed ID: 28724527
[TBL] [Abstract][Full Text] [Related]
35. Protein misfolding, functional amyloid, and human disease.
Chiti F; Dobson CM
Annu Rev Biochem; 2006; 75():333-66. PubMed ID: 16756495
[TBL] [Abstract][Full Text] [Related]
36. Quality control of the proteins associated with neurodegenerative diseases.
Gao X; Hu H
Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):612-8. PubMed ID: 18604452
[TBL] [Abstract][Full Text] [Related]
37. Synthetic prions and other human neurodegenerative proteinopathies.
Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
[TBL] [Abstract][Full Text] [Related]
38. Protein folding stress in neurodegenerative diseases: a glimpse into the ER.
Matus S; Glimcher LH; Hetz C
Curr Opin Cell Biol; 2011 Apr; 23(2):239-52. PubMed ID: 21288706
[TBL] [Abstract][Full Text] [Related]
39. Developing therapeutics for the diseases of protein misfolding.
May BC; Govaerts C; Cohen FE
Neurology; 2006 Jan; 66(2 Suppl 1):S118-22. PubMed ID: 16432139
[TBL] [Abstract][Full Text] [Related]
40. Role of molecular chaperones in neurodegenerative disorders.
Meriin AB; Sherman MY
Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
